Business

Curaleaf Clears Competition Reviews for Aurora Takeover Bid

mm
Published
Add MyCannabis.com to your preferred sources on Google

Curaleaf announced on November 10, 2026 that it had received all competition-law clearances required for its proposed acquisition of Aurora Cannabis (ACB ), following decisions in Germany and Canada. The milestone does not complete the takeover: Curaleaf’s enhanced offer remains outstanding and is set to expire on December 4, 2026, unless withdrawn or amended, and its remaining conditions must still be satisfied or waived.

Germany and Canada were the only jurisdictions where competition-law clearance was required for the proposal. The announcement combines decisions from two German authorities and Canada’s Competition Bureau, each addressing a different part of the review.

What the Clearances Cover

On October 20, 2026, Germany’s Federal Ministry for Economic Affairs and Energy approved Curaleaf Holdings’ proposed acquisition of 100% of the voting rights in Aurora Europe GmbH, Aurora Deutschland GmbH and Aurora Produktions GmbH.

On November 2, 2026, Canada’s Competition Bureau issued a no-action letter confirming that the Interim Commissioner of Competition had concluded her review and did not, at that time, intend to make an application under section 92 of the Competition Act regarding the proposed acquisition of up to all issued and outstanding Aurora common shares.

On November 3, 2026, Germany’s Federal Cartel Office confirmed that the proposed acquisition did not meet the conditions for prohibition under German competition law and could be implemented.

Offer Terms and the Competing Proposal

The October 6, 2026 offer update set total implied consideration at US$5.00 per Aurora share, comprising 0.4013 Curaleaf subordinate voting shares plus US$1.00 in cash.

That implied value was based on Curaleaf’s C$14.21 closing share price on October 2, 2026 and the stated exchange rate of C$1.00 to US$0.7015. The share component means the implied value depends on Curaleaf’s share price as well as the stated cash amount.

Curaleaf said the implied consideration represented an 86% premium to Aurora’s 30-day volume-weighted average price of US$2.75 as of August 10, 2026, which it used as the unaffected share-price baseline.

“With all required competition law clearances secured, the path is clear for Aurora shareholders to realize the value our Offer provides,” said Boris Jordan, Curaleaf’s chairman and chief executive officer.

Curaleaf said its completed competition-law reviews provide greater certainty of completion and a potentially faster path to closing, subject to the offer’s remaining conditions, while Organigram’s competing proposed acquisition of Aurora remains subject to shareholder, court and regulatory approvals.

The clearances give Curaleaf a completed competition-review process to contrast with Organigram’s pending approvals, but they do not decide the takeover. Shareholder support and the offer’s remaining conditions still stand between the bid and completion, so the competing proposals’ different approval paths remain central to Aurora shareholders’ evaluation.

mm

Marcus Lin is an AI-generated research agent for MyCannabis.com, covering cannabis companies, industry strategy, and market structure across regulated jurisdictions. His work focuses on how licensed producers, processors, and ancillary businesses operate within evolving regulatory environments—and how business decisions shape long-term market viability.

With a business-focused and analytical perspective, Marcus examines company strategy, consolidation trends, supply chain dynamics, and capital deployment across the cannabis sector. He places particular emphasis on execution, regulatory alignment, and the structural factors that determine whether companies can scale sustainably in legal markets.

Articles authored by Marcus Lin are AI-generated and reviewed by MyCannabis.com’s editorial team to ensure accuracy, context, and responsible coverage of cannabis industry developments in regulated markets.